Herbal-drug interaction induced rhabdomyolysis in a liposarcoma patient receiving trabectedin
© Strippoli et al.; licensee BioMed Central Ltd. 2013
Received: 7 January 2013
Accepted: 16 July 2013
Published: 30 July 2013
Rhabdomyolysis is an uncommon side effect of trabectedin which is used for the second line therapy of metastatic sarcoma after anthracycline and ifosfamide failure. This side effect may be due to pharmacokinetic interactions caused by shared mechanisms of metabolism involving the cytochrome P450 (CYP) system in the liver. Here, for the first time in literature, we describe the unexpected onset of heavy toxicity, including rhabdomyolysis, after the fourth course of trabectedin in a patient with retroperitoneal liposarcoma who at the same time was taking an alternative herbal medicine suspected of triggering this adverse event.
This is the case of a 56 year old Caucasian man affected by a relapsed de-differentiated liposarcoma who, after the fourth cycle of second-line chemotherapy with trabectedin, complained of sudden weakness, difficulty walking and diffuse muscle pain necessitating complete bed rest. Upon admission to our ward the patient showed grade (G) 4 pancytopenia and a marked increase in liver lytic enzymes, serum levels of myoglobin, creatine phosphokinase (CPK) and lactate dehydrogenase. No cardiac or kidney function injuries were present. Based on these clinical and laboratory features, our conclusive diagnosis was of rhabdomyolysis induced by trabectedin.
The patient did not report any trauma or muscular overexertion and no co-morbidities were present. He had not received any drugs during treatment with trabectedin, but upon further questioning the patient informed us he had been taking a folk medicine preparation of chokeberry (Aronia melanocarpa) daily during the last course of trabectedin and in the 2 subsequent weeks.
One week after hospitalization and cessation of intake of chokeberry extract, CPK and other markers of myolysis slowly returned to standard range, and the patient noted a progressive recovery of muscle strength.
The patient was discharged on day 14 when a blood transfusion and parenteral hydration gradually lowered general toxicity. Progressive mobilization of the patient was obtained as well as a complete normalization of the laboratory findings.
The level of evidence of drug interaction leading to the adverse event observed in our patient was 2 (probable). Thus our case underlines the importance of understanding rare treatment-related toxicities such as trabectedin-induced rhabdomyolysis and the possible role of the drug-drug interactions in the pathogenesis of this rare side effect. Furthermore, this report draws attention to a potential problem of particular concern, that of nutritional supplements and complementary and alternative drug interactions. These are not widely recognized and can cause treatment failure.
KeywordsTrabectedin related rhabdomyolysis Liposarcomas Drug-drug interactions Chokeberry (Aronia melanocarpa)-drugs interaction
Despite aggressive surgery and adjuvant radiotherapy, more than half of patients with soft tissue sarcoma develop a locally advanced or metastatic disease . Unfortunately there are very few active drugs for these patients. By far the most relevant change in this scenario is trabectedin, a drug isolated from the marine microorganism Ecteinascidia turbinate. Trabectedin was approved in Europe in 2007 as a single agent for second-line therapy of soft tissue sarcomas, and its activity is mainly relevant in liposarcoma and leiomyosarcoma .
While adverse reactions to trabectedin treatment such as neutropenia and liver function test alterations are well-known, more education and data are needed on some of the rare side effects mediated by this drug, such as the potential induction of rhabdomyolysis. A recent comprehensive safety analysis confirmed the uncommon occurrence of this side effect and also pointed out the need to avoid pharmacokinetic interactions with concomitant drugs caused by shared mechanisms of metabolism by the cytochrome P450 (CYP) system in the liver .
We describe here the unexpected onset of heavy toxicity including rhabdomyolysis after the fourth course of trabectedin in a patient with retroperitoneal liposarcoma who at the same time was taking an alternative herbal medicine suspected of triggering this adverse event. This report calls attention to a potential problem of particular concern, that of herbal-drug interaction. This problem is not widely recognized and can cause treatment failure in patients without an immediately obvious clinical modification.
This is the case of a 56 year old Caucasian man from Montenegro whose cancer history began in April 2009 after the appearance of progressive abdominal pain due to a retroperitoneum mass measuring 5 × 8 cm. The patient’s past medical record showed no relevant illness. He was an ex heavy smoker and did not drink alcohol or use illicit drugs. In May 2009 he underwent surgical removal of the abdominal mass achieving a complete margin negative (R0) resection. Histological findings of lesion specimens highlighted a low-grade de-differentiated liposarcoma. He then began follow-up. In November 2011 a computed tomography (CT) scan detected a new retroperitoneal lesion measuring 5 × 10 cm whose imaging features clearly suggested relapsed liposarcoma. He therefore underwent another radical surgery and the second histological examination supported the diagnosis of G2 de-differentiated liposarcoma with myxoid areas. Fluorescence in situ hybridization (FISH) analysis for oncogene murine double minute 2 (MDM2) status highlighted the amplification as highly specific diagnostic markers .
Behavior of laboratory parameters related to rhabdomyolysis starting from the first day of chemotherapy
White blood cell count
4-10 × 103/μl
1,7-7,6 × 103/μl
As the patient had this unusual muscular side effect after the fourth cycle of trabectedin, we explored possible sources that could trigger the potential trabectedin-induced rhabdomyolysis. He did not report any trauma or muscular overexertion. Due to the absence of co-morbidity, the patient had not received any other drugs during treatment with trabectedin. After further questioning in a non-threatening fashion, the patient informed us that he had been taking a commercial folk medicine preparation of chokeberry juice (Aronia melanocarpa) daily during the last course of trabectedin and in the 2 weeks after.
One week after hospitalization and stopping intake of chokeberry extract, CPK and other markers of myolysis slowly returned to standard range and the patient felt a progressive recovery of muscle strength.
The patient was discharged on day 14 when blood transfusion and parenteral hydration gradually reduced general toxicity. A progressive mobilization of the patient was obtained as well as a complete normalization of the laboratory findings (Table 1).
Discussion and conclusions
An overview of the most common herbal medicines involved in pharmacokinetic CYP interactions with chemotherapeutic drugs
Effect on metabolism
Saint John’s Wort
In our patient this “natural foe” was chokeberry (Aronia melanocarpa) extract derived from the black fruit of this shrub. This berry has a long tradition in European and North American folk medicine . It is a relatively concentrated source of flavonoids such as quercetin, and is also reported to strongly inhibit CYP3A4 activity in the liver. Consequently it is capable of increasing the bioavailability of different chemotherapeutic agents . Furthermore, the polyphenol anthocyanins in these berries are proven to have antioxidant properties which positively influence several risk factors for cardiovascular disease as well as anti-proliferative or protective effects against colon cancer [21, 22]. Several other substances such as sorbitol and polyphenols like laetrile advocated by some as a “cure” or a “preventative” for cancer are burdened by considerable doubt about their safety, and there are no proven beneficial effects for cancer patients .
From a clinical-pharmacological point of view, due to the evidence concerning decreased activities of enzymatic markers of CYP after forced feeding of chokeberry juice , the adverse event observed in our patient was secondary to the herbal-chemotherapy interaction with a level of evidence of 2 (probable) . However, there are limitations that deserve to be noted which should be appropriately handled in future studies: the idiosyncratic nature of trabectedin-related rhabdomyolysis; the patient’s pharmacokinetic parameters which have been altered by the cancer and the therapy itself; and the conceivable re-challenge with trabectedin after this side effect . Moreover, as the patient took a commercial preparation of chokeberry juice which did not provide information on the amounts of its compounds, it cannot be excluded that other interactions might have occurred such as the inhibition of transport mechanisms, the activation of the death receptor and other unknown mechanisms. Thus these potential interactions could occur not only with trabectedin but also with other chemotherapies. The development of medication databases linked to electronic screening programs is a useful tool that could help health professionals to identify dangerous herbal-drug combinations in the oncology setting .
In conclusion, our case underlines the importance of understanding rare treatment-related toxicities such as trabectedin-induced rhabdomyolysis and the possible role of the drug-drug interactions in the pathogenesis of this rare trabectedin side effect. Furthermore, in the presence of unexpected toxicity during conventional anticancer treatment, the simultaneous use by the patient of alternative drugs should be suspected. So a thorough medication history, enquiring about nutritional supplements and over-the-counter drugs, may help raise some red flags about potential interactions with chemotherapy.
Written informed consent was obtained from the patient for the publication of this report.
Oncogene murine double minute 2
Pegylated granulocytes colony stimulating factor
Eastern Cooperative Oncology Group
We would like to thank Caroline Oakley and Silvana Valerio for their assistance in the preparation of this manuscript.
- Clark MA, Fisher C, Judson I, Thomas JM: Soft-tissue sarcomas in adults. N Engl J Med. 2005, 353 (7): 701-711. 10.1056/NEJMra041866.View ArticlePubMedGoogle Scholar
- Demetri GD, Chawla SP, von Mehren M, Ritch P, Baker LH, Blay JY, Hande KR, Keohan ML, Samuels BL, Schuetze S, Lebedinsky C, Elsayed YA, Izquierdo MA, Gómez J, Park YC, Le Cesne A: Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules. J Clin Oncol. 2009, 27 (25): 4188-4196. 10.1200/JCO.2008.21.0088.View ArticlePubMedGoogle Scholar
- Grosso F, D’Incalci M, Cartoafa M, Nieto A, Fernandez-Teruel C, Alfaro V, Lardelli P, Roy E, Gomez J, Kahatt C, Soto-Matos A, Judson I: A comprehensive safety analysis confirms rhabdomyolysis as an uncommon adverse reaction in patients treated with trabectedin. Cancer Chemother Pharmacol. 2012, 69: 1557-1565. 10.1007/s00280-012-1864-4.View ArticlePubMedPubMed CentralGoogle Scholar
- Tanas MR, Goldblum JR: Fluorescence in situ hybridization in the diagnosis of soft tissue neoplasms: a review. Adv Anat Pathol. 2009, 16 (6): 383-391. 10.1097/PAP.0b013e3181bb6b86.View ArticlePubMedGoogle Scholar
- Stoyianni A, Kapodistrias N, Kampletsas E, Pentheroudakis G, Pavlidis N: Trabectedin-related rhabdomyolysis: an uncommon but fatal toxicity. Tumori. 2011, 97: 252-255.PubMedGoogle Scholar
- Grosso F, D’Incalci M: Problems in dealing with very rare adverse effects of new anticancer drugs: the example of trabectedin. Tumori. 2011, 97: 256-257.PubMedGoogle Scholar
- Brandon EF, Sparidans RW, Guijt KJ, Lowenthal S, Meijerman I, Beijnen JH, Schellens JH: In vitro characterization of the human biotransformation and CYP reaction phenotype of ET-743 (Yondelis, Trabectedin), a novel marine anti-cancer drug. Invest New Drugs. 2006, 24: 3-14. 10.1007/s10637-005-4538-9.View ArticlePubMedGoogle Scholar
- Riechelmann RP, Tannock IF, Wang L, Saad ED, Taback NA, Krzyzanowska MK: Potential drug interactions and duplicate prescriptions among cancer patients. J Natl Cancer Inst. 2007, 99: 592-600. 10.1093/jnci/djk130.View ArticlePubMedGoogle Scholar
- Milazzo S, Lejeune S, Ernst E: Laetrile for cancer: a systematic review of the clinical evidence. Support Care Cancer. 2007, 15: 583-595. 10.1007/s00520-006-0168-9.View ArticlePubMedGoogle Scholar
- Engdal S, Klepp MO, Nilsen OG: Identification and exploration of herb-drug combinations used by cancer patients. Integr Cancer Ther. 2009, 8: 29-36. 10.1177/1534735408330202.View ArticlePubMedGoogle Scholar
- Shi S, Klotz U: Drug interactions with herbal medicines. Clin Pharmacokinet. 2012, 51 (2): 77-104. 10.2165/11597910-000000000-00000.View ArticlePubMedGoogle Scholar
- Yang CY, Chao PD, Hou YC, Tsai SY, Wen KC, Hsiu SL: Marked decrease of cyclosporin bioavailability caused by coadministration of ginkgo and onion in rats. Food Chem Toxicol. 2006, 44 (9): 1572-1578. 10.1016/j.fct.2006.04.008.View ArticlePubMedGoogle Scholar
- Tang JC, Yang H, Song XY, Song XH, Yan SL, Shao JQ, Zhang TL, Zhang JN: Inhibition of cytochrome P450 enzymes by rhein in rat liver microsomes. Phytother Res. 2009, 23 (2): 159-164. 10.1002/ptr.2572.View ArticlePubMedGoogle Scholar
- Chow HH, Hakim IA, Vining DR, Crowell JA, Cordova CA, Chew WM, Xu MJ, Hsu CH, Ranger-Moore J, Alberts DS: Effects of repeated green tea catechin administration on human cytochrome P450 activity. Cancer Epidemiol Biomarkers Prev. 2006, 15 (12): 2473-2476. 10.1158/1055-9965.EPI-06-0365.View ArticlePubMedGoogle Scholar
- Obach RS: Inhibition of human cytochrome P450 enzymes by constituents of St. John's Wort, an herbal preparation used in the treatment of depression. J Pharmacol Exp Ther. 2000, 294 (1): 88-95.PubMedGoogle Scholar
- Anderson GD, Rosito G, Mohustsy MA, Elmer GW: Drug interaction potential of soy extract and Panax ginseng. J Clin Pharmacol. 2003, 43 (6): 643-648.View ArticlePubMedGoogle Scholar
- Hansen TS, Nilsen OG: In vitro CYP3A4 metabolism: inhibition by Echinacea purpurea and choice of substrate for the evaluation of herbal inhibition. Basic Clin Pharmacol Toxicol. 2008, 103 (5): 445-449. 10.1111/j.1742-7843.2008.00307.x.View ArticlePubMedGoogle Scholar
- Greenblatt DJ, Leigh-Pemberton RA, von Moltke LL: In vitro interactions of water-soluble garlic components with human cytochromes p450. J Nutr. 2006, 136: 806S-809S.PubMedGoogle Scholar
- Kulling SE, Rawel HM: Chokeberry (Aronia melanocarpa) – a review on the characteristic components and potential health effects. Planta Med. 2008, 74: 1625-1634. 10.1055/s-0028-1088306.View ArticlePubMedGoogle Scholar
- Choi JS, Piao YJ, Kang KW: Effects of quercetin on the bioavailability of doxorubicin in rats: role of CYP3A4 and P-gp inhibition by quercetin. Arch Pharm Res. 2011, 34 (4): 607-613. 10.1007/s12272-011-0411-x.View ArticlePubMedGoogle Scholar
- Lala G, Malik M, Zhao CW, He J, Kwon Y, Giusti MM: Anthocyaninrich extracts inhibit multiple biomarkers of colon cancer in rats. Nutr Cancer. 2006, 54: 84-93. 10.1207/s15327914nc5401_10.View ArticlePubMedGoogle Scholar
- Olas B, Wachowicz B, Tomczak A, Erler J, Stochmal A, Oleszek W: Comparative anti-platelet and antioxidant properties of polyphenol-rich extracts from: berries of Aronia melanocarpa, seeds of grape and bark of Yucca schidigera in vitro. Platelets. 2008, 19 (1): 70-77. 10.1080/09537100701708506.View ArticlePubMedGoogle Scholar
- Szaefer H, Krajka-Kuźniak V, Ignatowicz E, Adamska T, Baer-Dubowska W: Chokeberry (Aronia melanocarpa) juice modulates 7,12-dimethylbenz[a]anthracene induced hepatic but not mammary gland phase I and II enzymes in female rats. Environ Toxicol Pharmacol. 2011, 31 (2): 339-346. 10.1016/j.etap.2010.12.006.View ArticlePubMedGoogle Scholar
- Tatro DS: Drug interaction facts. 2009, St. Louis: Facts and ComparisonsGoogle Scholar
- Lamm W, Amann G, Brodowicz T: Case report of suspected Rhabdomyolysis during treatment with Trabectedin in a patient with Metastatic Leiomyosarcoma. Case Rep Oncol. 2010, 3: 477-479. 10.1159/000323261.View ArticlePubMedPubMed CentralGoogle Scholar
- Yap KY, Kuo EY, Lee JJ, Chui WK, Chan A: An onco-informatics database for anticancer drug interactions with complementary and alternative medicines used in cancer treatment and supportive care: an overview of the OncoRx project. Support Care Cancer. 2009, 10: 1011-1019.Google Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1472-6882/13/199/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.